Senescence-Associated Mitochondrial Dysfunction As A Therapeutic Target In Ovarian Cancer: Challenges And Opportunities
Our cells contain tiny powerhouses called mitochondria, which are crucial for energy production. However, as cells age, these mitochondria can become dysfunctional, a process known as senescence-associated mitochondrial dysfunction (SAMD). Recent findings suggest that this mitochondrial problem plays a significant role in how ovarian cancer develops resistance to treatments.
When mitochondria are damaged, their internal processes, like electron transport, don’t work correctly. This leads to a buildup of harmful molecules called reactive oxygen species (ROS). Think of ROS as cellular “rust” that can damage other parts of the cell. This chronic damage then triggers a cascade of events, leading to what scientists call a “senescence-associated secretory phenotype” (SASP).
SASP is essentially a collection of signals, including inflammatory proteins and factors that promote blood vessel growth, released by these dysfunctional cells. These signals act like a distress call, but instead of helping, they actually change the environment around the tumor, making it more hospitable for cancer cells and, crucially, more resistant to therapies that would normally kill them.
Understanding these intricate connections between aging mitochondria and cancer resistance opens up new possibilities. Scientists are now exploring whether targeting these mitochondrial dysfunctions could be a way to make ovarian cancer treatments more effective and overcome drug resistance.
Source: link to paper